The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
NEW YORK, Aug. 9, 2024 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Disease." Winners will be announced during the Prix Galien USA Awards Ceremony on November 7, 2024, at the American Museum of Natural History in New York City.
"We are thrilled to recognize the outstanding achievements of those who have devoted their expertise to advancing healthcare and improving lives, globally," said Michael Rosenblatt, MD, Chair of the Prix Galien USA Awards Committee, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc. "The annual Prix Galien Awards highlight the continuous pursuit of innovation and the remarkable contributions of this year's nominees."
The 2024 Prix Galien USA nominees include products from the following categories: "Best Biotechnology Product" - 21 nominees; "Best Pharmaceutical Product" - 25 nominees; and "Best Product for Rare/Orphan Diseases" - 8 nominees.
To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact.
Best Biotechnology Product (Nominees)
Amgen and AstraZeneca
TEZSPIRE(R)
Arcutis Biotherapeutics, Inc.
ZORYVE(R)
argenx
VYVGART(R)
AstraZeneca and Sanofi
Beyfortus(R)
BeiGene
Brukinsa(R)
Daiichi Sankyo & AstraZeneca
ENHERTU(R)
Genmab and AbbVie
EPKINLY(R)
GSK
AREXVY
Innoviva Specialty Therapeutics, Inc.
XACDURO(R)
Ipsen
Bylvay(R)
Jazz Pharmaceuticals
Rylaze(R)
Johnson & Johnson
TALVEY(TM)
Johnson & Johnson
TECVAYLI(TM)
Johnson & Johnson and Legend Biotech
CARVYKTI(R)
Merck & Co Inc.
CAPVAXIVE(TM)
MGI Tech
DNBSEQ-T20
Pfizer Inc.
PREVNAR 20(R)
Pfizer Inc.
ABRYSVO(R)
Regeneron and Sanofi
Dupixent(R)
VBI Vaccines Inc. PreHevbrio(TM)
XVIVO Perfusion XPS with STEEN
Solution
Best Pharmaceutical Product (Nominees)
AbbVie
ELAHERE(R)
Alkermes, Inc
LYBALVI(R)
Ardelyx, Inc.
XPHOZAH(R)
Aurinia Pharmaceuticals Inc.
LUPKYNIS(R)
Biogen Inc. and Sage Therapeutics
ZURZUVAE(R)
Eisai and Biogen Inc.
LEQEMBI(R)
Eli Lilly and Company
Kisunla(TM)
Genentech, A Member of the Roche
Ocrevus(R)
Group
Genentech, A Member of the Roche
PHESGO(R)
Group
Genentech, A Member of the Roche
VABYSMO(TM)
Group
Gilead Sciences
Sunlenca(R)
Glaukos Corporation
iDose(R) TR
Incyte
Opzelura(R)
Ironshore
JORNAY PM (R)
Johnson & Johnson
RYBREVANT(R)
Merck & Co. Inc.
WINREVAIR(TM)
Mirum Pharmaceuticals, Inc. LIVMARLI(R) (maralixibat) oral
solution
Novartis
PLUVICTO(R)
Pfizer Inc.
CIBINQO(R)
Pfizer Inc.
PAXLOVID(TM)
Phathom Pharmaceuticals VOQUEZNA(R) (vonoprazan)
Sanofi
Tzield(R)
Servier Pharmaceuticals
TIBSOVO(R)
Sumitomo Pharma America, Inc.
Myfembree(R)
ViiV Healthcare Apretude (cabotegravir extended-
release
injectable suspension)
Best Product for Rare/Orphan Diseases (Nominees)
AstraZeneca and Ionis Pharmaceuticals WAINUA(TM)
Biogen Inc. SKYCLARYS (R)
Biogen Inc. and Ionis Pharmaceuticals QALSODY(R)
Immunocore KIMMTRAK(R)
Marinus Pharmaceuticals, Inc. ZTALMY(R)
Regeneron Evkeeza(R)
Sanofi Xenpozyme(R)
SpringWorks Therapeutics OGSIVEO(R)
"Each year, we have the honor of convening in New York City to celebrate the groundbreaking achievements that are improving health and longevity for all," said Bruno Cohen, Chairman of The Galien Foundation. "This event celebrates the invaluable contributions from researchers, scientists and innovators who work tirelessly to inspire excellence and dedication within the industry."
The Prix Galien USA Awards Committee is composed of 11 renowned leaders from the biomedical industry and academia, including three Nobel Laureates, responsible for evaluating nominees.
Prix Galien Biotechnology, Pharmaceutical and Rare/Orphan Diseases Awards Committee 2024
Michael ROSENBLATT
M.D., Galien Forum Co-Chair, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc.
Prix Galien Committee Chair
Linda BUCK
Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington
Sue DESMOND-HELLMANN
M.D., M.P.H., Former Chief Executive Officer, Bill & Melinda Gates Foundation
Laurie GLIMCHER
M.D., President and CEO, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School
Mary-Claire KING
Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington
Robert S. LANGER
M.D., David H. Koch Institute Professor, Massachusetts Institute of Technology
Cato T. LAURENCIN
M.D., Ph.D., Chief Executive Officer, The Cato T. Laurencin Institute at UConn; The University Professor and Van Dusen Distinguished Endowed Professor, University of Connecticut
Steven J. LESTER
M.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator
Stanley B. PRUSINER
M.D., Nobel Laureate, Professor of Neurology, Director, Institute for Neurodegenerative Diseases, University of California, San Francisco
Phillip A. SHARP
Ph.D., Nobel Laureate, Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic
Marc TESSIER-LAVIGNE
Ph.D., President Emeritus and Professor, Stanford University
About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The late Professor Elie Wiesel, 1986 Peace Nobel Laureate, is The Honorary Founding President of The Galien Foundation
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
For more information, visit?www.galienfoundation.org.
Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/
Media Contact:
Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2024-prix-galien-usa-nominees-for-best-biotechnology-product-best-pharmaceutical-product-and-best-product-for-rareorphan-diseases-302218512.html
SOURCE The Galien Foundation
